Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PD-1/IL-2Ra/IL-2 fusion protein REGN10597

An antibody fusion protein composed of an antibody fragment targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and fused to the endogenous cytokine interleukin-2 (IL-2) and masked with an antibody fragment directed against the IL-2 receptor subunit alpha (IL2Ra; CD25) binding-site on IL-2, with potential immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/IL-2Ra/IL-2 fusion protein REGN10597 targets and binds to PD-1 expressed on PD-1-expressing T cells in the tumor microenvironment (TME), thereby specifically bringing IL-2 to the PD-1-positive T cells in the TME. The PD-1 binding specifically induces a confirmational change in REGN10597 that allows its IL-2 moiety to bind to the IL-2Ra expressed on PD-1-positive CD8+ T effector cells and natural killer (NK) cells, thereby activating IL2Ra-mediated signaling within these immune cells. The activation of cytotoxic T-lymphocytes (CTLs) and NK cells mediate cytolytic immune responses against tumor cells causing tumor cell destruction and inhibition of tumor cell proliferation. By selectively activating PD-1 positive T cells with IL-2, but not PD-1 negative bystander or naïve T cells, the activity of tumor specific T cells is specifically enhanced while IL-2-induced systemic toxicity is decreased. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. The receptor-masked IL-2 allows for specific activation of IL-2 in the presence of PD-1-positive cells in the TME.
Synonym:PD-1-targeted receptor-masked IL-2 immunocytokine REGN10597
Code name:REGN 10597
REGN-10597
REGN10597
Search NCI's Drug Dictionary